December 2025 Quarterly Activities Report and Appendix 4C
Filed with ASX · · 9 pages · English
Story so far
Earlier from TrivarX
- Positive results from US-veteran mental health trial
- TRI Exercises Option to Advance Acquisition of Stabl-Im
- September 2025 Quarterly Activities Report and Appendix 4C
- US-veteran mental health trial patient recruitment complete
- Acquisition of Stabl-Im technology and Private Placement
Later from TrivarX
- Appendix 4D & Half-Year Financial Report to 31 December 2025
- Dr Danielle Meyrick appointed as CEO
- March 2026 Quarterly Activities Report and Appendix 4C
- CRO Engaged to Advance Stabl-Im Phase 1 Trial
- Stabl-Im clinical trial supply milestone achieved
Follow TrivarX into a list and get an email when it puts out news.
Follow TrivarX